
|Articles|April 15, 2004
FDA expedites review of kidney cancer drug
The FDA has added BAY 43-9006, an investigational treatment for metastatic renal cell carcinoma, to its fast track program.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
ORIC-944 shows promise in combination with ARPIs for mCRPC
2
Radioligands and ADT alternatives emerge in prostate cancer treatment
3
Jason Hafron, MD, recaps prostate cancer data from ESMO 2025
4
Beyond PSA: Jonathan Henderson, MD, on precision tools for prostate cancer
5


















